Coherus Oncology (CHRS) Inventory Average (2019 - 2026)

Coherus Oncology's Inventory Average history runs 8 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, Inventory Average rose 3.52% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 3.52% YoY), while the FY2025 annual figure was $3.7 million, down 88.96% from the prior year.
• Inventory Average came in at $4.0 million for Q1 2026 at Coherus Oncology, up from $2.6 million in the prior quarter.
• In the past five years, Inventory Average ranged from a high of $65.4 million in Q3 2023 to a low of $2.6 million in Q4 2025.
• A 5-year average of $34.6 million and a median of $34.3 million in 2022 frame the typical range for Inventory Average.
• Across the five-year window, Inventory Average surged 119.92% in 2023 and tumbled 94.02% in 2025, its largest moves.
• Coherus Oncology's Inventory Average stood at $33.3 million in 2022, then jumped by 94.54% to $64.7 million in 2023, then plunged by 59.93% to $25.9 million in 2024, then plunged by 89.93% to $2.6 million in 2025, then soared by 53.2% to $4.0 million in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $4.0 million, $2.6 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison